Should adults, especially those ≥50 years old or immunocompromised, receive the recombinant zoster vaccine promptly after recovering from COVID‑19 infection or COVID‑19 vaccination despite the transient increase in shingles risk?

Prompt Shingrix Vaccination After COVID-19 Infection or Vaccination

Yes—adults ≥50 years and immunocompromised adults ≥18 years should receive the recombinant zoster vaccine (Shingrix) promptly after recovering from COVID‑19 infection or COVID‑19 vaccination, without delay, because the substantial long‑term benefit of preventing herpes zoster and postherpetic neuralgia far outweighs the small, transient increase in shingles risk documented in the immediate post‑COVID period. 1, 2

Evidence for Increased Herpes Zoster Risk After COVID‑19

• COVID‑19 infection increases herpes zoster risk by 2.16‑fold (95% CI: 1.24–3.76) compared to uninfected individuals, with a 21% higher risk following COVID‑19 hospitalization (adjusted incidence rate ratio 1.21; 95% CI: 1.03–1.41). 3, 4

• In contrast, COVID‑19 vaccination does not significantly increase herpes zoster risk when compared to unvaccinated controls (relative risk 1.08; 95% CI: 0.84–1.39), indicating no sustained association between vaccination and shingles. 3

• Among post‑vaccination herpes zoster cases, 60.1% occurred after the first COVID vaccine dose and 66.7% within the first week, with the majority (44.6%) resolving within 10 days and 50% within one month—demonstrating a transient, self‑limited phenomenon rather than a sustained risk. 3

Rationale for Prompt Shingrix Administration

• Shingrix demonstrates 97.2% efficacy against herpes zoster in adults ≥50 years (ZOE‑50 trial) and 91.3% efficacy in adults ≥70 years, with 88.8% efficacy against postherpetic neuralgia in the older cohort. 1, 5

• Real‑world vaccine effectiveness studies confirm 73.9% effectiveness (95% CI: 71.8%–75.8%) against herpes zoster and 83.7% effectiveness (95% CI: 75.1%–89.3%) against postherpetic neuralgia over a median follow‑up of 4 years, with durable protection remaining stable through this period. 6

• Protection persists for at least 8 years with efficacy above 83.3%, declining to approximately 73% at 10 years—far superior to the live‑attenuated Zostavax, which drops to only 14.1% efficacy by year 10. 1, 5

• The 10‑year cumulative recurrence risk of herpes zoster is 10.3%, underscoring that even a prior shingles episode does not confer reliable long‑term immunity and vaccination remains essential. 1

Vaccination Timing and Schedule

Immunocompetent Adults ≥50 Years

• Administer the first Shingrix dose immediately once acute COVID‑19 symptoms (fever, severe malaise) have resolved; no mandatory waiting period is required after COVID‑19 infection or vaccination. 1, 7

• Give the second dose 2–6 months after the first dose, with a minimum interval of 4 weeks. 1, 2

• If a patient had a prior herpes zoster episode, wait at least 2 months after acute symptoms resolve before administering Shingrix, but this interval does not apply to post‑COVID timing. 1

Immunocompromised Adults ≥18 Years

• For immunocompromised adults (including those with hematologic malignancies, solid‑organ transplant recipients, HIV infection, autoimmune diseases on immunosuppressive therapy, or JAK inhibitors), administer the first dose immediately after COVID‑19 recovery. 1, 2

• Use a shortened schedule with the second dose given 1–2 months after the first dose to achieve earlier protection, while respecting the 4‑week minimum interval. 1, 2

• Ideally complete the full 2‑dose series before initiating or resuming highly immunosuppressive therapy (e.g., JAK inhibitors, high‑dose chemotherapy) to maximize immune response, but do not delay necessary treatment if vaccination cannot be completed beforehand. 1

Safety and Tolerability

• Shingrix is associated with higher rates of grade 3 injection‑site reactions (9.5% vs 0.4% placebo) and systemic symptoms (11.4% vs 2.4% placebo), but these are transient, mild‑to‑moderate, and resolve within approximately 4 days. 1

• Serious adverse events and mortality are no different between vaccine and placebo groups, confirming a favorable safety profile. 1, 8

• Shingrix can be safely administered to patients on low‑dose glucocorticoids (prednisone equivalent <10 mg/day) without adversely impacting vaccine response. 1

Critical Caveats and Pitfalls

• Never use live‑attenuated Zostavax in immunocompromised patients or those about to start immunosuppressive therapy; only Shingrix is appropriate because the live vaccine carries a risk of disseminated VZV infection. 1, 2

• Do not delay Shingrix vaccination to wait for antibody titers or to allow more time after COVID‑19 infection/vaccination; the transient post‑COVID shingles risk is far outweighed by the long‑term protection Shingrix provides. 1, 3

• Do not confuse the waiting period after an acute herpes zoster episode (≥2 months) with the timing after COVID‑19 infection or vaccination, which requires no mandatory interval. 1

• Ensure completion of the 2‑dose series; one‑dose vaccine effectiveness is only 60.3% (95% CI: 56.4%–63.9%) against herpes zoster and 45.6% (95% CI: 11.4%–66.6%) against postherpetic neuralgia, significantly lower than the two‑dose series. 6

• If a patient previously received Zostavax, administer Shingrix at least 2 months after the last Zostavax dose, as Zostavax provides inadequate long‑term protection. 1

Algorithm for Clinical Decision‑Making

1. Confirm patient eligibility:

   • Age ≥50 years (immunocompetent) or age ≥18 years (immunocompromised). 1, 2

2. Assess COVID‑19 status:

   • If acute COVID‑19 symptoms (fever, severe malaise) are present, wait until symptoms resolve. 1, 7
   • If patient recently received COVID‑19 vaccination, no waiting period is required. 1

3. Check for prior herpes zoster episode:

   • If yes, ensure ≥2 months have elapsed since acute symptoms resolved. 1
   • If no prior episode, proceed immediately. 1

4. Determine dosing schedule:

   • Immunocompetent adults ≥50 years: second dose at 2–6 months. 1, 2
   • Immunocompromised adults ≥18 years: second dose at 1–2 months. 1, 2

5. Optimize timing for immunosuppressive therapy:

   • If feasible, complete the 2‑dose series before starting or resuming immunosuppressive therapy. 1
   • If urgent therapy is required, administer at least the first dose before initiation. 1

6. Counsel patient on expected side effects:

   • Injection‑site pain, fatigue, myalgia, and headache are common but resolve within ≈4 days. 1

7. Ensure second‑dose completion:

   • If the second dose is delayed beyond the recommended interval, do not restart the series; administer the second dose as soon as possible. 1